Ignite Creation Date:
2025-12-24 @ 11:48 AM
Ignite Modification Date:
2025-12-29 @ 6:50 PM
Study NCT ID:
NCT05296161
Status:
RECRUITING
Last Update Posted:
2022-04-28
First Post:
2022-02-18
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis
Sponsor:
Amsterdam UMC, location VUmc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-04-20
Start Date Type:
ACTUAL
Primary Completion Date:
2024-04
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-03
Completion Date Type:
ESTIMATED
First Submit Date:
2022-02-18
First Submit QC Date:
None
Study First Post Date:
2022-03-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-04-21
Last Update Post Date:
2022-04-28
Last Update Post Date Type:
ACTUAL